A sharp, opinionated take pushes back on claims that GLP-1 weight-loss drugs are somehow “fascistic,” arguing the Left has drained the word of meaning and that real-world health and economic facts undercut the rhetoric. The piece highlights quotes from a socialist activist and responses on social media, lays out the financial stakes tied to obesity, and questions the motives driving the body positivity debate. It keeps the focus on the clash between ideology and medical reality while preserving direct quotations and key figures. The tone is skeptical of the Left’s framing and leans into concerns about public health, control, and accountability.

The word “fascist” has been lobbed so often by the Left that it barely registers anymore, which matters because language shapes how we judge ideas. Terms like racist, bigot, homophobe, and Nazi were stretched thin long before this, and “fascist” has now joined that list of overused labels. When everything is labeled a crime against liberty, real threats get lost in the noise.

Recently a socialist activist went further, calling GLP-1 weight-loss drugs “fascistic” and tying their use to structural oppression. The claim is startling on its face because GLP-1s are medical treatments prescribed by doctors, not political manifestos. The argument centers on context, not individual choice, but that context claim deserves scrutiny.

“The political deployment of GLP-1s is fascistic. Not because individuals take them, but because the conditions under which they become necessary are shaped by a world fixated on genociding fat people,” he said. That quote is dramatic and built to provoke, but it still needs to be weighed against medical realities and incentives. If the concern is systemic pressure, show the mechanisms, don’t just rebrand medical care as ideology.

“This is a structural critique that asks what happens when the conditions produced by capitalism, by public health, by the state apparatus, and by anti-black desire align around a single bodily ideal that leaves little to no room for divergence and punishes any body that does,” Harrison continued. “Whereas earlier diet drugs were often associated with vanity or addiction, GLP-1s are positioned as responsible medicine, promising relief rather than restraint.” Those are heavy claims about institutions and racialized desire, and they deserve a clear evidentiary trail. Tossing in Frantz Fanon references does not replace concrete proof.

“But to understand why the deployment of GLP-1s is fascistic requires turning to Frantz Fanon’s account of black flesh under colonial surveillance,” Harrison added. Um, what? That leap from clinical therapies to colonial surveillance theory reads like an attempt to elevate outrage over practical questions about safety, access, and outcomes. It’s a rhetorical flourish that risks alienating people who want straightforward answers.

Another social post pushed the claim even further, claiming the concept of a daily caloric intake was “dictated by slavers trying to figure out the minimum amount they could feed enslaved people without being sued for them taking food from others. The health complex was built on experimentation on Black populations.” She also called Harrison’s insane views “a fair take.” You may not be able to view that account now, but the line of argument is clear: historical abuses are being used as a lens to condemn modern medical practice.

https://x.com/thestustustudio/status/2096379112093016241

There is clearly money and control embedded in the modern body positivity debate, or critics like Harrison wouldn’t be so focused on labeling weight-loss drugs as “fascistic.” The idea that entire movements hinge solely on virtue signaling ignores plain incentives in health care, insurance, and politics. Call it socialized medicine or centralized control, and the result is the same: policy choices influence who pays for what and who ends up dependent on public systems.

Obesity is expensive in measurable terms. On average, adult obesity costs the U.S. healthcare system more than $170 billion per year; childhood obesity costs about $1.3 billion. That works out to an adult with obesity spending at least $1,861 extra per year and a severely obese adult spending about $3,097 more, due to extra visits, hospital stays, procedures, specialized equipment, and medications.

If you were designing incentives to expand government control over health spending, having a larger cohort with chronic, preventable conditions would be strategically useful. The suggestion that some prefer dependency over individual responsibility is a political judgment, but it’s rooted in plausible incentives. Those incentives deserve debate rather than sloganeering about genocide.

Speaking as someone with health-care experience and a long personal fight against excess weight, telling Black Americans that a doctor-prescribed therapy is inherently racist risks doing real harm. Black Americans already face higher rates of heart disease, Type 2 diabetes, hypertension, and respiratory conditions; excess weight amplifies those risks dramatically. Framing potentially life-improving treatments as ideological attacks can discourage people from seeking care that might extend their lives.

The human cost is already visible. In recent years, people once celebrated by body positivity circles—like reality and social media personalities—have died young from complications associated with severe obesity. Dolly Martinez, Jamie Lopez, Brittany Sauer, and Taylor LeJeune all died in their 20s and 30s, often with heart or metabolic complications following prolonged extreme obesity. Those outcomes aren’t rhetorical points; they are losses that deserve honest discussion about prevention and treatment.

Not long ago, advertising cycles favored plus-sized models, but companies have shifted back toward healthier body types as effective treatments and aesthetic trends change. The sudden disappearance of many plus-sized faces from mainstream ads coincided with GLP-1s making weight loss achievable for many people. Correlation is not proof of conspiracy, but it’s evidence of market forces reacting to medical advances. In that sense, the debate should focus on outcomes, incentives, and patient welfare—not on weaponizing loaded political labels. Remind me what the definition of fascism is again?